Company News /
by Adrian Tan -
4 months ago
04 Dec 2024 - Alterity Therapeutics (ASX:ATH) has completed the Phase 2 clinical trial in multiple system atrophy for ATH434, its lead drug candidate.
Company Presentations /
by Finance News Network -
2 years ago
13 Mar 2023 - Dr David Stamler, CEO - Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenera…
Market Reports /
by Melissa Darmawan -
4 years ago
07 Jan 2021 - It has been a terrific day of trade for the ASX. After opening modestly higher, the ASX 200 shot up in the first 10 minutes of trade, then gained momentum at a steady…
Interviews /
by Rachael Jones -
4 years ago
09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its du…
Interviews /
by Katrina Bullock -
5 years ago
09 Jul 2019 - Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug candidate PTB434 for use treating…
